ArticleOpen medicine (Warsaw, Poland)2026
Safety study of sitagliptin combined with metoprolol on the treatment of elderly patients with type 2 diabetes mellitus and hypertension.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Sitagliptin is a standard therapeutic option for type 2 diabetes mellitus (T2DM), while metoprolol is an antihypertensive agent. This study aimed to assess the safety of their combination therapy in elderly patients with T2DM and hypertension. Methods: Medical data of 52 elderly patients with T2DM and hypertension from June 2021 to March 2024 were retrospectively collected. According to different treatment methods, 52 patients were categorized into the sitagliptin + metoprolol group (n=26) and the sitagliptin group (n=26). After a 12-week treatment period, the baseline characteristics, therapeutic efficacy and biochemical indicators were analyzed between groups. Results: After 12-week treatment, both groups exhibited significant improvements in therapeutic efficacy, immune-inflammatory status, coagulation function, and liver-kidney function (p<0.05). Compared with the sitagliptin group, the sitagliptin + metoprolol group showed better therapeutic efficacy, with lower FPG, HbA Conclusions: Short-term observation indicates that sitagliptin combined with metoprolol can improve blood glucose, blood pressure, inflammation, coagulation, and liver-kidney function in elderly patients with T2DM and hypertension, without a significant increase in the risk of adverse reactions during short-term follow-up. However, as a single-center, small-sample retrospective study, the present findings should be interpreted as preliminary clinical evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.